in endometrial and cervical cancer (1–4), we wanted to evaluate the expression of cytokeratin 19 (CK19) in vulvar carcinomas in order to perform intraoperative SLNB using OSNA. Methodology. The expression of CK19 was studied in 23 paraffin tissues from vulvar biopsies diagnosed with squamous cell carcinoma from Donostia Hospital from January 2021 to December 2022. And 25 cases from Navarra Hospital from January 2021 to November 2022. Results. The total number of biopsies studied were 48. Of the 23 biopsies of Donostia Hospital, 6 were CK 19 positive (26%). However, in 25 biopsies of Navarra Hospital, CK19 positivity was observed in 10 (40%). Among positive cases, a different rate of staining was observed (8–95%). None of the positive cases was associated with HPV.

A relatively different rate of CK19 expression was observed between centers. One of them approaching the percentage found in another published study (5). On the other hand, the highly diverse rate found in the two hospitals also presents similarities to the difference in CK19 expression described in cervical carcinomas (5–7).

Conclusion. Despite showing various positivities and in some cases of low rate, the fact of its existence makes considering the study of CK19 with immunohistochemistry in a protocol manner in biopsies of vulvar squamous cell carcinoma; patients who show such positivity could benefit from the intraoperative SLNB study with OSNA, increasing the detection of micrometastases, and avoiding the complications derived from a second intervention.

Disclosures. NONE

#612 RECONSTRUCTIVE SURGERY IN THE TREATMENT OF VULVAR STENOSIS AFTER RADICAL INTERVENTIONS IN PATIENTS WITH VULVAR CANCER

Elena Leonidovna Dikareva, Oksana Aslanovna Zhamborova, Amina Dzharbaeova Dzharbaeva, Veronika Andreeneva Artemenko, Igor Evgenyevich Govorov, Elena Aleksandrovna Ulrikh*, Almazov National Medical Research Centre, Saint-Petersburg, Russia

10.1136/ijgc-2023-ESGO.826

Introduction/Background. Surgery remains the most efficient method in treatment of vulvar cancer. With a locally advanced disease, extensive operations are required leading to gross scarring of the perineal tissues, vaginal stenosis, dysuric phenomena, pain, and altered sexual life.

Methodology. We propose a method for surgical correction of cicatricial changes of the perineum in patients with malignant neoplasms of the vulva following radical vulvectomy.

Results. Since 2018, 8 patients have been admitted to the Almazov National Research Medical Center with complaints of impaired urination (delay, soreness, difficulty, stream deviation), pain in the perineum, and altered sexual function caused by gross scarring in the perineum. All patients (n = 8) had previously undergone radical vulvectomy due to vulvar cancer, three along with postoperative radiation therapy. The average period from surgery to the occurrence of clinically significant changes was 5.8 years, with the earliest manifestations occurring after 21 months in one patient. All patients had a history of drug and/or photodynamic therapy without effect. We performed excision of scar-altered perineal tissues with simultaneous wound defect reconstruction with moved skin-fascial flaps from the posterior thighs’ surfaces. In all cases (n = 8), there were no signs of necrosis or flap ischemia. The use of this surgical method for closing a wound defect (figure 1) minimized the likelihood of postoperative complications leading to the formation of scar tissue changes in the perineum and significantly improved the quality of life of patients, the assessment of which was carried out using FACT-G questionnaires (Version 4, 2002).

Conclusion. The use of reconstructive plastic surgery with moved fasciocutaneous flaps from the posterior surfaces of the thighs after excision of scar-altered perineal tissues to correct scarring of perineal tissues after vulvectomy is a promising method of treatment.

Disclosures. Nothing to disclose

#626 THE USE OF PLASMAJET® IN THE TREATMENT OF VULVAR INTRAEPITHELIAL NEOPLASIA: RESULTS FROM 48 PATIENTS IN A UK GYNAECOLOGICAL CANCER CENTRE

Natasha Rinne*, Shriya Varghese, Stacey Bryan, Benjamin Jones, Sadaf Ghaem-Maghami, Sid JAN, James Richard Smith, Department of Gynaecology Oncology, Hammersmith Hospital, West London Gynaecological Cancer Centre, Imperial College London, London, UK

10.1136/ijgc-2023-ESGO.827

Introduction/Background. Incidence rates of vulvar cancer have risen by over 17% since the 1990s. Development is secondary to cellular changes resulting in vulvar intraepithelial neoplasia (VIN), with VIN II and III carrying an increased risk of developing in to malignancy. Wide local excision is considered the gold standard treatment. Plasmajet®, a relatively new device designed to produce a jet of natural argon plasma used to vaporise tissues, is being used in laparoscopic/open treatment of a number of malignancies as an alternative to tumour excision. To date, long-term data on safety and outcome of the use of Plasmajet® on the vulva is lacking. Here we describe the largest UK series of VIN treatment with Plasmajet® in gynaecological surgery.